Metrics to compare | ELAB | Sector Sector - Average of metrics from a broad group of related Basic Materials sector companies | Relationship RelationshipELABPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −5.8x | 11.9x | |
PEG Ratio | - | −0.03 | 0.03 | |
Price/Book | 1.4x | 2.3x | 1.5x | |
Price / LTM Sales | 18.6x | 3.6x | 0.9x | |
Upside (Analyst Target) | - | 86.8% | 21.2% | |
Fair Value Upside | Unlock | 15.0% | 11.0% | Unlock |
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company’s lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.